Clinical Report: FDA Grants Traditional Approval to Iptacopan in Primary IgAN
Overview
The FDA has granted traditional approval to iptacopan for slowing kidney function decline in adults with primary IgA nephropathy at risk of progression. This approval follows earlier accelerated approval based on findings from the phase 3 APPLAUSE-IgAN trial.
Background
Primary immunoglobulin A nephropathy (IgAN) is a significant kidney disease characterized by the accumulation of IgA antibodies, leading to inflammation and potential kidney damage. The recent approval of iptacopan is based on findings from the phase 3 APPLAUSE-IgAN trial.
Data Highlights
Parameter
Iptacopan
Placebo
Annualized mean decline in eGFR (mL/min/1.73 m²/year)
3.0
5.7
Key Findings
Iptacopan significantly slowed the decline in kidney function compared to placebo.
Reductions in proteinuria were observed as early as 2 weeks and sustained throughout the treatment period.
The most common adverse events included abdominal pain, dizziness, and nausea.
Iptacopan may increase the risk of serious infections from encapsulated bacteria.
The approval was based on data from the phase 3 APPLAUSE-IgAN trial.
Clinical Implications
Monitoring for adverse events, particularly serious infections, is essential when prescribing this medication.
Conclusion
The traditional approval of iptacopan was granted based on findings from the phase 3 APPLAUSE-IgAN trial.
Seven companies will participate in a two-phase program that provides early FDA technical guidance during development of new US pharmaceutical manufacturing facilities.
Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.
